Clinical and genetics aspects of the lipid profile in women with autoimmune thyroiditis

Aim:

in women with Hashimoto's disease (HD) we studied the clinical and some molecular genetic characteristics of the lipid profile.

Materials and Methods:

Subjects for this study included 109 women with HD. The average age of 57.2 ± 7.8 years, disease duration 8.0 ± 6.4 years, menopause duration 6.4 ± 3.5 years. Control group consisted of 85 women of similar age without thyroid pathology. Clinical and anthropometric data was collected from all participants. Whole blood samples were drawn in the morning after an overnight fasting for the measurement of serum TSH, free thyroxine (FT4), anti-thyroid peroxidase antibody (TPO-Ab) levels, as well as lipid concentrations and glucose. In genetic research participated 441 women: 104 women with HD and 337 healthy women (control subjects). The genotype of the subjects for TaqIB polymorphism of CETP, rs320 (HindIII +/-) polymorphism of LPL, polymorphism of the coding portion of the gene APOE, rs2228314 (1784G/C) polymorphism of SREBF2 was analyzed by using polymerase chain reaction-restriction fragment length polymorphism.

Results:

Stratified by triglycerides (TG) level increased in subjects with HD and lowered levels of cholesterol of high density lipoproteins (HDL). Similar results were obtained when comparing the indexes of blood lipids in the group of women who have reached the level of TSH in the range of 0.4–2.5 mU/l on the background of ongoing substitution therapy with thyroid hormone. Not received the differences in the distribution of genotypes of the polymorphisms of the gene CETP Taq1B, rs320 LPL gene and ɛ2/ɛ3/ ɛ4 APOE gene, rs2228314 SREBF2 gene in the main and control groups. B1B1 TaqIB polymorphism of CETP of the main group had the higher levels of TG and BMI. ɛ3/ɛ4 APOE had the higher levels of total cholesterol, LDL cholesterol, cholesterol non-HDL in women with hypothyroidism.

Conclusion:

In women with compensated hypothyroidism TG levels above and below the level of HDL cholesterol compared to the control. Shown association of APOE and CETP gene with some lipids parameters.

1. Фадеев В.В. Заболевания щитовидной железы в регионе легкого йодного дефицита: эпидемиология, диагностика, лечение. – М.: Издательский дом Видар-М; 2005. – 240 с. [Fadeyev VV. Zabolevaniya shchitovidnoy zhelezy v regione legkogo yodnogo defitsita: epidemiologiya, diagnostika, lechenie. Moscow: Vidar-M; 2005. 240 p. (in Russ)]

2. Рымар О.Д., Мустафина С.В., Симонова Г.И., и др. Эпидемиологические исследования йодного дефицита и тиреоидной патологии в крупном центре Западной Сибири в 1995–2010 гг. (на примере Новосибирска) // Клиническая и экспериментальная тиреоидология. – 2012. – Т. 8. – №2. – С. 50–54. [Rymar OD, Mustafina SV, Simonova GI, et al. Epidemiological evaluation of iodine deficiencyand thyroid disorders in the megalopolis of western Siberia in 1995–2010. Clinical and experimental thyroidology. 2012;8(2):50-54. (In Russ)] doi: 10.14341/ket20128250-54.

3. Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014;94(2):355-382. doi: 10.1152/physrev.00030.2013.

4. Cooper DS, Halpern R, Wood LC, et al. L-Thyroxine Therapy in Subclinical Hypothyroidism. Ann Intern Med. 1984;101(1):18. doi: 10.7326/0003-4819-101-1-18.

5. NystrÖM E, Caidahl K, Fager G, et al. A Double-blind cross-over 12-month study of l-thyroxine treatment of women with ‘subclinical’ hypothyroidism. Clin Endocrinol (Oxf). 1988;29(1):63-76. doi: 10.1111/j.1365-2265.1988.tb00250.x.

6. Jaeschke R, Guyatt G, Gerstein H, et al. Does treatment withl-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med. 1996;11(12):744-749. doi: 10.1007/bf02598988.

7. Kong WM, Sheikh MH, Lumb PJ, et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. The American Journal of Medicine. 2002;112(5):348-354. doi: 10.1016/s0002-9343(02)01022-7.

8. Meier C, Staub J-J, Roth C-B, et al. TSH-Controlledl-Thyroxine Therapy Reduces Cholesterol Levels and Clinical Symptoms in Subclinical Hypothyroidism: A Double Blind, Placebo-Controlled Trial (Basel Thyroid Study). J Clin Endocr Metab. 2001;86(10):4860-4866. doi: 10.1210/jcem.86.10.7973.

9. Razvi S, Ingoe L, Keeka G, et al. The Beneficial Effect ofl-Thyroxine on Cardiovascular Risk Factors, Endothelial Function, and Quality of Life in Subclinical Hypothyroidism: Randomized, Crossover Trial. J Clin Endocr Metab. 2007;92(5):1715-1723. doi: 10.1210/jc.2006-1869.

10. Caraccio N, Ferrannini E, Monzani F. Lipoprotein Profile in Subclinical Hypothyroidism: Response to Levothyroxine Replacement, a Randomized Placebo-Controlled Study. J Clin Endocr Metab. 2002;87(4):1533-1538. doi: 10.1210/jcem.87.4.8378.

11. Monzani F, Caraccio N, Kozàkowà M, et al. Effect of Levothyroxine Replacement on Lipid Profile and Intima-Media Thickness in Subclinical Hypothyroidism: A Double-Blind, Placebo- Controlled Study. J Clin Endocr Metab. 2004;89(5):2099-2106. doi: 10.1210/jc.2003-031669.

12. Boekholdt SM. Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects. Circulation. 2005;111(3):278-287. doi: 10.1161/01.cir.0000153341.46271.40.

13. Ridker PM, Pare G, Parker AN, et al. Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction: Genomewide Analysis Among 18 245 Initially Healthy Women From the Women's Genome Health Study. Circ Cardiovasc Genet. 2009;2(1):26-33. doi: 10.1161/circgenetics.108.817304.

14. Шахтшнейдер Е.В., Рагино Ю.И., Полонская Я.В., и др. Ассоциация HindIII полиморфизма гена LPL с формированием липидного профиля сыворотки // Атеросклероз. – 2014. – Т. 10. – №2. – С. 24–30. [Shakhtshneider EV, Ragino YI, Polonskaya YV, et al. Association HINDIII polymorphism LPL with the formation of lipid profile serum. Ateroskleroz. 2014;10(2):24-30. (In Russ)]

15. Воевода М.И., Шахтшнейдер Е.В., Максимов В.Н., и др. Полиморфизм гена аполипопротеина Е и атеросклероз // Атеросклероз. – 2008. – Т. 4. – №1. – С. 11–26. [Voevoda MI, Schakhtschneider EV, Maximov VN, et al. Polymorphism of Apolipoprotein E gene and atherosclerosis. Ateroskleroz. 2008;4(1):11-26. (In Russ)]

16. Gutekunst R, Martin-Teichert H. Requirements for Goiter Surveys and the Determination of Thyroid Size. In: Iodine Deficiency in Europe. Section 1. NATO ASI Series. Vol. 241. Springer US; 1993:109-118. doi: 10.1007/978-1-4899-1245-9_12.

17. Никитин Ю.П., Малютина С.К., Макаренкова К.В., Щербакова Л.В. Особенности липидного профиля крови у женщин предпенсионного и пенсионного возраста // Атеросклероз. – 2014. – Т. 10. – №3. – С. 41–45. [Nikitin YP, Malyutina SK, Makarenkova KV, Shcherbakova LV. Features of the lipid profile of blood in women of pre-retirement and retirement age. Ateroskleroz. 2014;10(3):41-45. (In Russ)]

18. Pearce SHS, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013;2(4):215-228. doi: 10.1159/000356507.

19. Ito M, Arishima T, Kudo T, et al. Effect of Levo-Thyroxine Replacement on Non-High-Density Lipoprotein Cholesterol in Hypothyroid Patients. J Clin Endocr Metab. 2007;92(2):608-611. doi: 10.1210/jc.2006-1605.

20. Шахтшнейдер Е.В., Куликов И.В., Максимов В.Н., и др. Полиморфизм гена CETP в европеоидной популяции западной Сибири и группах, контрастных по уровню общего холестерина сыворотки // Бюллетень экспериментальной биологии и медицины. – 2014. – Т. 157. – №3. – С. 343–347. [Shakhtshneider EV, Kulikov IV, Maksimov VN, et al. CETP Gene Polymorphism in the Caucasian Population of West Siberia and in Groups Contrast by Total Serum Cholesterol Levels. Bull Exp Biol Med. 2014;157(3):364-367.] doi: 10.1007/s10517-014-2567-0.

21. Diekman MJM, Anghelescu N, Endert E, et al. Changes in Plasma Low-Density Lipoprotein (LDL)- and High-Density Lipoprotein Cholesterol in Hypo- and Hyperthyroid Patients Are Related to Changes in Free Thyroxine, Not to Polymorphisms in LDL Receptor or Cholesterol Ester Transfer Protein Genes. J Clin Endocr Metab. 2000;85(5):1857-1862. doi: 10.1210/jcem.85.5.6595.

22. Lambrinoudaki I, Kaparos G, Rizos D, et al. Apolipoprotein E and Paraoxonase 1 polymorphisms are associated with lower serum thyroid hormones in postmenopausal women. Clin Endocrinol (Oxf). 2009;71(2):284-290. doi: 10.1111/j.1365-2265.2008.03476.x.